European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk

Open Access
Publisher Website
Google Scholar
Abstract
Atherosclerotic cardiovascular disease (ASCVD) underlies the thrombotic events intimately associated with myocardial infarction, a significant proportion of ischaemic strokes, as well as critical limb ischaemia. Such events confer substantial mortality, physical and/or mental disability, and cost for the individual and society.1 Indeed, no finite value can be attributed to the cost to the individual, although survival and subsequent quality of life are critical factors, especially in young individuals with ASCVD.2 Although the advent of precision medicine and innovative treatments have been the driver for an individualized approach to patient management and prevention, the ever-increasing financial restraints in healthcare systems worldwide often require clinical benefit to be balanced with the cost of a given intervention.